JPRN-jRCT2080221636未知3 期
The Effect Of Transthyretin Stabilization, Safety, Tolerability, Efficacy And Pharmacokinetics Of Orally Administered Tafamidis In Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin: A Phase 3, Open-Label(B3461010)
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Transthyretin amyloid polyneuropathy with V30M or non-V30M transthyretin mutation.
排除标准
- •-Primary amyloidosis and secondary amyloidosis.
- •-History of liver transplant.
研究者
相似试验
已完成
3 期
The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M TransthyretinTransthyretin Familial Amyloid PolyneuropathyNCT01435655Pfizer10
进行中（未招募）
1 期
The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients with Non-V30M Transthyretin Amyloidosis - Not applicableon-V30M Transthyretin AmyloidosisEUCTR2007-006791-12-FRFoldRx Pharmaceuticals, Inc.16
进行中（未招募）
不适用
The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients with Non-V30M Transthyretin Amyloidosis - Not applicableEUCTR2007-006791-12-DEFoldRx Pharmaceuticals Limited24
进行中（未招募）
不适用
The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients with Non-V30M Transthyretin Amyloidosis - NDPatients with Non-V30M Transthyretin AmyloidosisMedDRA version: 9.1Level: LLTClassification code 10016202Term: Familial amyloidosisEUCTR2007-006791-12-ITFOLDRX PHARMACEUTICALS, INC.16
已完成
2 期
The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin AmyloidosisTransthyretin-associated Amyloidosis With PolyneuropathyNCT00630864Pfizer21